Qiwen Fang

[Rainee Yang @RaineeYang_HKU]

Our latest study has been published in
@AnnalsofIM. The DOAC group had a higher 1-year risk of stroke than warfarin in Asian AF-MS patients. We also found that rivaroxaban increased the risk of stroke, while non-rivaroxaban DOACs did not.
Full paper: https://t.co/6Nq1kxVJMj

[Eric YF Wan @EricWan_HKU]

Our @Age_and_Ageing paper found that lowering BP of <130/80 mmHg in old and very old patients was associated with better #cardiovascular and #mortality outcomes without increased adverse events, suggesting a lower BP target may be safe for older patients.
https://t.co/6apws5xE5o

[Eric YF Wan @EricWan_HKU]

Our target trial emulation analysis on @NatureComms provides evidence for a BP target of <130/80 mmHg in clinical guidelines for the treatment of adult HT patients in primary care, with a lower risk of HT-related #complications and all-cause #mortality.

https://t.co/FKdSn7pcnx

[Eric YF Wan @EricWan_HKU]

Our interrupted time series analysis on @JournalofNeph illustrates the indirect effect of the #COVID-19 on Chronic Kidney Disease #CKD patients in Hong Kong, as delayed #CVD diagnoses and increased #mortality rate were seen among non-COVID CKD patients.

https://t.co/MH9zY1jGdo

[Eric YF Wan @EricWan_HKU]

Our @amjmed paper confirms the substantial economic burden of smoking to Hong Kong despite its low #smoking prevalence. Healthcare costs for women and middle-aged smokers are disproportionately higher, and targeted #cessation programs can be a solution.

https://t.co/qMEPhV6nLu

[Celine Chui HKU @ChuiCeline]

P-CARDIAC is highly receptive among clinicians and patients. It shows promise in monitoring cardiovascular health and feasibility in implementing in primary care. #AIHealth #cardiology @NatalieTsie @ChunKaWong @hkumed @hku_son @HkuPharm

https://t.co/SGLV8P5DFF

[Xinya Mu @Silvia1536629]

Happy to share my first PhD paper in Pharmacological Research 🎉

Using a Japanese claims database, we found that concomitant use of quetiapine and Bupleuri Radix (Chaihu)-containing formulations was associated with increased risk of acute adverse events.

https://t.co/qy8Stf8HLa

[Claire Cuiling WEI @clairewei0830]

Our paper on trends in migraine-specific medication consumption across 73 countries is out now in Journal of Headache and Pain, as part of the collection “2026 Early Career Research Mentorship Program”. 🎉
🔗https://t.co/Ya0rqrmuX8

[Qiwen Fang @Cheevnn]

A survey led by Prof David Coghill from the University of Melbourne as part of the Lancet Psychiatry Series on ADHD.
General population survey: https://t.co/b97aUmrRwK

[Eric YF Wan @EricWan_HKU]

Our publication at Chinese Journal of General Practitioners introduces #HongKong #Chronic Disease Co-Care Pilot Scheme #CDCC, which can achieve better health outcomes by early #screening and #intervention while lowering overall medical #expenditure.
https://t.co/qEp2b0tFa0

[Eric YF Wan @EricWan_HKU]

We found in the early phase of the #Chronic Disease Co-Care #CDCC Pilot Scheme, #glycemic, #bloodpressure, #lipid, and #BMI indicators improved among #PreDM, #T2DM and #HT patients, with particularly pronounced effects in males and those younger than 65.
https://t.co/u0VbK0cHAa

[Yin Zhang @zhangyin0904]

Happy to share our study on global Clostridioides difficile infection treatment trends in International Journal of Antimicrobial Agents. Use of fidaxomicin and oral vancomycin is rising globally, but access remains unequal across regions and incomes.
🔗 https://t.co/eKc7XdUTTq

[Jack Lau @jackilau]

Happy to share our study on Pneumococcal disease epidemiology on International Journal of Infectious Diseases:
Children and adolescents had an elevated risk of gaining antimicrobial resistance, suggesting more measures to reduce S. pneumoniae infections

https://t.co/x0pvnqkL2q

[Franco WT Cheng @kfranco_c]

Our new study is out! We looked at anaemia treatments (ESAs) and fracture risk in CKD patients.

Prolonged ESA use seems linked to a higher risk of osteoporotic fractures. This suggests we need to optimise treatment to balance benefits vs. risk. Full text: https://t.co/h3GtofA46m

[Franco WT Cheng @kfranco_c]

Our new meta-analysis in Hypertension Research confirms Sacubitril/Valsartan effectively reduces both office and out-of-office blood pressure.

This was a fantastic international collaboration with our colleagues at Chulalongkorn University.

https://t.co/gzOjOurHA4

[Monash Health Law @MonashHealthLaw]

Digitally Enabling High-Touch and High-Impact #Antimicrobial Use in #EndofLife Care

@CalvinWLHo @ChuiCeline & Chia-Chin Lin

@Cancer_Nursing ➡️ https://t.co/S6LpzJtPKN
#PublicHealth #Bioethics #HealthLaw @MonashLawSchool @HKUCMEL @HKU_SoN @HKUMed

[Callie Caige Huang @Callie_Huang123]

Excited to share our latest study in @LancetRH_WPac : Psychotropic medication consumption increased globally after the onset of the COVID-19 pandemic, with variations in consumption patterns observed across different countries. @Esther_CSMPRHKU
https://t.co/umLRvID1Tl

[Luna Wei Yue @WeiYLuna]

Excited to share our latest study in @TheLancet: long-acting injectable antipsychotics (LAIAs) are more effective than oral and equally safe for older people, except for higher risk of EPS with typical LAIAs, but not with atypical LAIAs. @Esther_CSMPRHKU
https://t.co/xQB0YitlVz

[Eric YF Wan @EricWan_HKU]

Our @CMAJ study found a less stringent #risk threshold of 30% for intensifying #PrimaryCare encounters frequency is associated with increased overall #CVD risks and all-cause #mortality of aged 60+ #T2DM patients, but not for those below 60.
https://t.co/zNwz2HTKNd

[Eric YF Wan @EricWan_HKU]

Our age-specific models accurately predicted the post-acute #mortality risk within 1 year of #COVID infection, optimizing clinical strategies and resource allocation in global burden of #LongCOVID management. Published on @_qjm_.
https://t.co/KypBNSfUyJ